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The DOT1L histone H3 lysine 79 (H3K79) methyltransferase plays an oncogenic role in MLL-
rearranged leukemogenesis. Here, we demonstrate that, in contrast to MLL-rearranged leu-
kemia, DOT1L plays a protective role in ultraviolet radiation (UVR)-induced melanoma
development. Speciﬁcally, the DOT1L gene is located in a frequently deleted region and
undergoes somatic mutation in human melanoma. Speciﬁc mutations functionally compro-
mise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
Importantly, in the absence of DOT1L, UVR-induced DNA damage is inefﬁciently repaired, so
that DOT1L loss promotes melanoma development in mice after exposure to UVR.
Mechanistically, DOT1L facilitates DNA damage repair, with DOT1L-methylated H3K79
involvement in binding and recruiting XPC to the DNA damage site for nucleotide excision
repair (NER). This study indicates that DOT1L plays a protective role in UVR-induced
melanomagenesis.
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The epigenetic landscape of cells, comprising a combinationof DNA methylation and hydroxymethylation togetherwith posttranslational histone modiﬁcations, is a crucial
determinant in the establishment and maintenance of gene
expression programs that govern cell identity. Thus it is not
surprising that disease-associated alterations in the function of
histone-modifying complexes disrupt the pattern and levels of
histone marks and DNA methylation and consequently dereg-
ulate the control of chromatin-based processes1. Importantly,
deregulation of epigenetic processes can contribute to transfor-
mation and the development of cancer. For example, genome-
wide mapping of 5-hydroxymethylcytosine (5-hmC), an inter-
mediate in cytosine dimethylation mediated by the TET enzymes,
revealed that loss of 5-hmC is an epigenetic hallmark of mela-
noma, with diagnostic and prognostic implications2. Histone
methylation, catalyzed by a group of histone methyltransferases,
takes place on both lysine (K) and arginine (R) residues3. Unlike
other modiﬁed histone N-terminal “tail” residues, H3K79 is
exposed on the nucleosome surface and methylated within the
globular domain4,5. The yeast protein Dot1 and human homolog
DOT1L are responsible for catalyzing H3K79 mono-, di- and tri-
methylation5,6. DOT1L-dependent H3K79 methylation is asso-
ciated with telomere silencing, meiotic checkpoint control,
modulation of constitutive heterochromatin, transcriptional
activation, and DNA repair7,8.
Nucleotide excision repair (NER) is a particularly critical
process that removes DNA damage induced by ultraviolet
radiation (UVR), requiring the coordinated action of about 30
proteins9. In mammals, NER removes UVR-induced photo-
products, including cyclobutane-pyrimidine dimers (CPDs) and
6–4 pyrimidine-pyrimidone photoproducts (6–4 PPs). The xer-
oderma pigmentosum, complementation group C (XPC) com-
plex, containing RAD23B and centrin 2, recognizes DNA lesions
and initiates global genome NER. However, as CPDs do not
create helix distortions that can be directly recognized by XPC,
the DDB1/DDB2 complex is required to stabilize DNA con-
formation and assist XPC binding after UVR10. After the initial
recognition step, repair proteins, such as XPA, and TFIIH com-
plex including the essential subunit p62, bind to the damage site,
which promotes recruitment of other NER factors. This allows
incision of the damaged strand by repair endonucleases, including
ERCC1/XPF and XPG and restoration of the normal nucleotide
sequence11.
In leukemogenesis, DOT1L has a well-established role in which
it frequently interacts with mixed lineage leukemia (MLL)
oncogenic fusion proteins, such as AF4, ENL, ELL, and AF1012,13,
to induce H3K79 methylation and constitutively activate a leu-
kemic transcriptional program resulting in transformation14,15.
Inhibition of DOT1L enzymatic activity, or disruption of the
interaction between DOT1L and the MLL fusion proteins, is a
promising therapeutic strategy for the treatment of MLL fusion-
related leukemia16. EPZ-5676, a small-molecule inhibitor of
DOT1L, has been evaluated for MLL-rearranged leukemia in
Phase I clinical trials (clinicaltrials.gov, EPZ-5676-12-001/
NCT01684150/). Here tumor genome sequencing efforts have
identiﬁed inactivating mutations in DOT1L in 4.4–15% of mela-
nomas. Importantly, in the absence of DOT1L, UVR-induced
DNA damage is inefﬁciently repaired such that DOT1L loss
promotes melanoma development in mice after exposure to UVR.
Results
Identiﬁcation of DOT1L mutations in human melanoma.
GISTIC analysis of SNP6 data for somatic copy number variation
(CNV) and similar GISTIC analysis17 show that one common
deletion region in melanoma chr19p13.3 (chr19:1-2166394)
overlaps DOT1L (q value = 0.006) (Fig. 1a). Among all 83 genes in
the CNV chr19:1-2166394 region, we did not ﬁnd any other genes
involved in the response to DNA damage based on analysis by the
Gene Ontology Consortium18.
To explore how DOT1L might function in melanoma
development, we analyzed somatic mutation data of melanomas
collected from The Cancer Genome Atlas (TCGA) data portal
and found 427,383 somatic variant calls made from 470 human
samples (tumor samples with matched normal control) spanning
19,563 distinct genes. These included 37 somatic mutations of
DOT1L annotated by the ANNOVAR algorithm19. Synonymous
mutations or nonsynonymous mutations without deleterious
effects as predicted by SIFT score (SIFT_Pred ﬂag=D) were
excluded20 leaving 23 somatic mutations with likely deleterious
effects. All of them are point mutations and singletons, except one
(chr19:2225413), which is detected in two samples (Supplemen-
tary Data 1). This is consistent with the ﬁnding that these
mutated residues occur with extremely low variant frequency
(<0.001) (Supplementary Data 2) and are usually evolutionarily
conserved (GERP++ score >2).
To determine whether the rate of deleterious mutation in DOT1L
is signiﬁcantly higher than in other genes, we conducted a gene-
based burden test21. Speciﬁcally, we created 1 supervariant for each
gene by combining all the singletons and variants within it using the
following rules: for each sample, (a) the deleterious ﬂag was set to 1,
if there was at least 1 deleterious somatic mutation observed; (b)
otherwise, the deleterious ﬂag was set to 022. For this melanoma
cohort (n = 470), the 19,563 genes exhibit an average deleterious
mutation rate of 0.011649. For the DOT1L gene, we ﬁnd that
21 samples have at least 1 predicted deleterious somatic mutation,
namely, the deleterious rate is 21/470 = 0.045, which is signiﬁcantly
higher than the average (p value = 6.44 × 10−8) (Fig. 1b).
We also detected 33 missense somatic mutations using the
GATK and MuTect/VarScan algorithms from both melanoma
tissues and paired germline DNA samples, which is similar to the
ANNOVAR algorithm (Fig. 1c and Supplementary Fig. 1).
Speciﬁcally, missense DOT1L mutations were identiﬁed in 4.4%
(21/473) of TCGA melanomas, 5.8% (7/121) in the Broad
Institute Database (2012)23 and 15.0% (3/20) in the Broad
Institute Database (2015)24 (Fig. 1c), a similar mutation rate to
that observed for some well-characterized melanoma drivers,
such as IDH1 and CDK423. Notably, 75.8% (25/33) missense
mutations are C-T or CC-TT UVB signature mutations (Fig. 1c,
Supplementary Fig. 1 and Supplementary Data 3).
Next, we sought to understand the biological signiﬁcance of
DOT1L in melanomas. We treated melanoma cells with different
doses of the DOT1L inhibitor EPZ-5676 and assessed its effects
on H3K79 methylation and cell growth. Consistently, we found
that DOT1L inhibition reduced H3K79me2 levels (Supplemen-
tary Fig. 2a) and blocked MV411 and Molm14 MLL-rearranged
leukemia cell growth in a dose-dependent manner but not the
growth of human primary melanocytes (HPMs) or melanomas,
including UACC62, A375, C021, C052, A04, and B16 (Supple-
mentary Fig. 2b–d). Furthermore, we investigated the role of
DOT1L absence on cell growth in non-MLL arranged leukemia
HL-60 and normal HPM cells. Speciﬁcally, the DOT1L gene was
silenced using speciﬁc shDOT1L and the resulting polyclonal cell
lines were assayed for H3K79 methylation and cell growth using
cell counting and 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl
tetrazolium bromide (MTT) assays. The result showed that
DOT1L-targeted inhibition inhibited H3K79 methylation in all
cell lines and speciﬁcally inhibited cell growth in leukemia cells
with MLL translocations such as MV411, but not in melanoma
cells, or leukemia without MLL translocations, such as HL-60
(Supplementary Fig. 2e). These results are consistent with
previous reports that DOT1L-targeted inhibition selectively kills
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MLL-rearranged leukemia cells but has little impact on leukemia
cells without MLL rearrangements25.
DOT1L mutations in human melanoma are loss of function.
We then examined the effects of DOT1L mutations on H3K79 di-
methylation on four cell lines, D11, D28, D22, and C025, derived
from human melanomas with missense mutations. Exome
sequencing of these cell lines showed that one of them, D11, has
loss of heterozygosity at DOT1L (Supplementary Data 4). Endo-
genous expression of wild-type (WT) and mutant DOT1L was
analyzed and comparable levels of DOT1L protein were observed
in all cell lines with the exception of C025 that contains a mono-
allelic truncation mutation (Supplementary Fig. 3a). Notably,
levels of H3K79 methylation markedly decreased in cells with
DOT1L mutations in comparison to cells with WT DOT1L
(C021), with the DOT1L mutations detected in all the detected
melanoma cell lines indicated (Fig. 2a and Supplementary Fig. 3b).
To conﬁrm this result, we re-introduced WT or mutant
DOT1L into DOT1L-silenced HPMs and then measured di-
methylated H3K79. In cells that had their endogenous DOT1L
silenced, expression of exogenous WT DOT1L increased H3K79
di-methylation, whereas expression of the M55L, P271L, and
P505L and Q1017X mutants did not (Fig. 2b, upper panel).
Similarly, expression of WT DOT1L in MV411 leukemia
increased H3K79 methylation, whereas mutant DOT1L proteins
failed to do so (Fig. 2b, lower panel). These results and results
from similar experiments in C021, A375, and UACC62
melanoma cells as well as 293T cells suggest that DOT1L
mutations found in human melanomas likely have impaired
methyltransferase activity, rather than having dominant-negative
effects (Supplementary Fig. 3c).
To understand the signiﬁcance of the DOT1L mutations on
their defective function, we examined the crystal structure of the
DOT1L catalytic domain (1–416) solved by Min et al.26 showing
residues 4–332 in the ordered structure. This revealed that a
ﬂexible loop and the C-terminal region of the structure is
responsible for binding to the co-factor S-(5′-adenosyl)-L-
methionine (SAM), which acts as the methyl group donor during
methylation of the nucleosomal histones (Supplementary Fig. 3d).
Based on methyl group donor (SAM) orientation and computa-
tional docking26, a substrate-binding interface of the C-terminal
catalytic domain was proposed. Two of the mutations identiﬁed
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Fig. 1 Identiﬁcation of DOT1L mutations in human melanoma. a Somatic CNVs identiﬁed by GISTIC analysis of SNP6 data. Signiﬁcantly deleted
chromosome regions are shown. The deletion in red contains the DOT1L gene. b Gene-based burden test by ANNOVAR. c Percentages of melanoma
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in the study, M55L and P271L, are in the N-terminal catalytic
domain. While M55 is in the N-terminal region of the catalytic
domain and away from the SAM binding pocket, P271 resides in
the C-terminal SAM-binding region. Interestingly, M55 and P271
are also located at the interface between DOT1L and its
nucleosomal histone substrate. Both mutations, M55L and
P271L, retain the hydrophobicity of the positions. The M55L
mutant has a longer but less bulky side chain, likely affecting the
local conformation in the vicinity in a modest fashion. Mutation
P271L most likely introduces extra ﬂexibility into the backbone
region. These results suggest that the modest conformational
changes caused by mutations at positions 55 and 271 may affect
the recognition of nucleosomal histones by the catalytic domain
and consequently the catalytic efﬁciency of the methyltransferase.
To validate this analysis, we tested whether the mutations affect
DOT1L chromatin recognition and binding. Using a chromatin
fractionation assay, we observed that the M55L and P271L
mutations in DOT1L dramatically reduced its association with
histone substrate (Supplementary Fig. 3e), suggesting that these
mutations impair DOT1L in recognizing its histone substrate and
thereby compromise DOT1L’s histone methyltransferase func-
tion. Similar results were obtained using the P505L mutant. While
P505 is not located in the catalytic center, PolyPhen 2.2.2 analysis
suggested that the P505 mutation would result in a conforma-
tional change that is likely to account for its failure to tightly
associate with chromatin. These observations are consistent with
our cellular studies (Fig. 2a, b).
To determine the impact of mutated DOT1L in regulating
proliferation, WT and M55L, P271L, and P505L DOT1L
expression constructions were introduced into MV411 leukemia
cells or HPMs and cell growth after treatment with the DOT1L
inhibitor EPZ-5676 was analyzed using cell counting (Fig. 2c) and
an MTT assay (Fig. 2d). In MV411 cells, the expression of WT
DOT1L partially reversed the effect of the inhibitor, whereas no
enhanced proliferation was seen on expression of any of the
mutants. By contrast, in HPMs, the DOT1L inhibitor, WT, or
mutant DOT1L did not show the obvious effect on cell
proliferation (Fig. 2c, d). Collectively, these results suggest that
while DOT1L regulates leukemia cell proliferation it does not play
a major role in regulating normal melanocyte growth.
To further explore the roles of DOT1L in melanomas,
chromatin immunoprecipitation–sequencing (ChIP-seq) assays
of H3K79me2 in C021 cells with and without short hairpin RNA
(shRNA) silencing of DOT1L and in C025 cells bearing a DOT1L
mono allelic loss-of-function mutation were performed. In
agreement with previous reports27, the H3K79me2 ChIP-seq
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peaks were enriched in gene bodies, with the strongest signal
observed immediately downstream of transcription starting sites
(Fig. 2e). Furthermore, either silencing or mutation of DOT1L
resulted in a global decrease of H3K79me2 enrichment. These
results indicated that disease-associated DOT1L mutations have
decreased methyltransferase activity and reduced levels of
H3K79me2 across the genome.
In order to interrogate whether DOT1L has cancer-type-
speciﬁc targets, we compared our results with another study that
performed H3K79me2 ChIP-seq assays in a leukemia cell line
MV411 with and without the treatment of the DOT1L inhibitor
SGC094628. In leukemia, the H3K79me2 enrichment was
abnormal in amount and distribution, which is associated with
rearranged MLL target loci27,29,30. Our study identiﬁed 1518
genes whose gene body regions contain sites with decreased
H3K79me2 levels in the DOT1L-mutant melanoma cell line C025
and shDOT1L-treated cell line C021. We analyzed the data from
the other study and identiﬁed 1508 genes whose gene body
regions contain sites with signiﬁcantly decreased H3K79me2
levels in the DOT1L inhibitor-treated leukemia cell line MV411.
We refer to those genes as DOT1L-target genes. We found that
406 DOT1L-target genes (~27% for either melanoma or
leukemia) are shared between the melanoma and leukemia cell
lines (Supplementary Fig. 4a). For instance, DOT1L targets the
MYB gene locus in the MV411 leukemia cells but not in the C021
or C025 melanoma cells (Supplementary Fig. 4b). This is also the
case for HOXA9 and RUNX1, which are well-known DOT1L-
target genes in MLL-rearranged leukemia29,31. In contrast,
DOT1L targets the DDB1 gene locus only in melanoma cell
lines (Supplementary Fig. 4b). While the DDB1 gene body is
enriched with H3K79me2 in both MV411 and C021 cell lines,
DOT1L inhibition only results in a signiﬁcant decrease in the
H3K79me2 level in C021 cells. Taken together, the different
pattern of DOT1L/H3K79me2 in melanoma vs. leukemia cells
suggest a different role of DOT1L/methylated H3K79 in
melanoma compared to leukemia.
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DOT1L mutations promote melanomagenesis with
BRAFV600E. To ask whether mutated DOT1L or DOT1L silen-
cing might affect UVR-induced melanomagenesis, we used
immortalized human primary melanocytes (hTERT/p53DD/
CDK4(R24C))32 to establish polyclonal cell lines expressing
shDOT1L or an shRNA control with or without the additional
expression of BRAFV600E (Fig. 3a). These immortalized melano-
cytes form anchorage-independent colonies in the presence of
both BRAFV600E mutation and pretreatment with low dose of
UVB (20 J m−2)33,34. Those cells were subjected to clonogenic
survival and anchorage-independent growth assays. Our results
from the colony formation and soft agar assays revealed that
BRAFV600E-mediated cellular transformation was dramatically
enhanced by DOT1L silencing (Fig. 3b, c). We also re-introduced
WT and mutant DOT1L into DOT1L-depleted hTERT/p53DD/
CDK4(R24C)/BRAFV600E melanocytes (Fig. 3d), with colony
formation and soft agar growth assays indicating that only WT
DOT1L efﬁciently rescued DOT1L silencing-induced cellular
transformation (Fig. 3e, f). Moreover, to examine the effect of
DOT1L on tumor growth in vivo, hTERT/p53DD/CDK4(R24C)/
BRAFV600E DOT1L-depleted melanocytes were inoculated sub-
cutaneously into each ﬂank of nude mice. Examination of
xenograft tumor volumes and weight indicated that loss of
DOT1L promoted xenograft formation (Fig. 3g–i). All results
indicate that DOT1L silencing is a helper in melanomagenesis
and that, in the presence of activated oncogenes, such as
BRAFV600E, loss of DOT1L facilitates oncogenic transformation.
UVR-induced melanoma development in DOT1L knockout
mice. To better deﬁne the role of DOT1L in melanocytes and
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UVR-induced melanoma development in vivo, we speciﬁcally
depleted DOT1L expression in melanocytes using conditional
Dot1l knockout mice (Dot1lﬂox/ﬂox), in which exon 2 of Dot1l was
ﬂoxed. Cre-mediated excision of exon 2 leads to a frame shift
mutation to inactivate Dot1l35. Transgenic mice expressing Cre-
ERT2 protein under the control of the tyrosinase (Tyr) pro-
moter36 were crossed with Dot1lﬂox/ﬂox mice with tamoxifen
administration depleting Dot1l in melanocytes leading to loss of
functional Dot1l mRNA (Supplementary Fig. 5a). Mice were
given a dose of 500 J m−2 UVB irradiation each week for 4 weeks
and then incidence of melanoma was observed for another
10 weeks (Fig. 4a). WT mice (n = 11) were treated with both UVB
irradiation and tamoxifen administration. Dot1lﬂox/ﬂox/Tyr-
CreERT2 mice (n = 6) with tamoxifen administration but without
UVB irradiation served as controls and no melanoma incidence
was observed in the control mice. Notably, 46.7% (n = 7/15) of
UVB-irradiated Dot1lﬂox/ﬂox/Tyr-CreERT2 mice with tamoxifen
administration developed melanoma (Fig. 4b, c). No hyperpig-
mentation or nevi were found in Dot1lﬂox/ﬂox/Tyr-CreERT2 mice
without UVB irradiation nor in the WT DOT1L mice with UVB
irradiation. The melanomas closely resembled human vertical
growth phase melanoma and were composed of epithelioid and
spindle cells with ﬁne pigmentation in the cytoplasm. The nuclei
of the tumor cells are enlarged with some having small nucleoli,
and melanophages were scattered within the tumors (Fig. 4d).
Strong S-100, Melan-A/Mart-1, Tyrosinase (Tyr) and Pax3
expression was detected in all tumors (Fig. 4e). These results
indicate that melanoma development in melanocyte-speciﬁc
Dot1l knockout mice is UVR dependent.
To characterize the molecular characteristics of Dot1l-null
melanoma, we measured the mRNA expression of neural crest
development genes, tumor-suppressor genes, and oncogenes in
melanoma development by quantitative reverse-transcriptase
PCR (qRT-PCR). We found Pax3 and Tyrosinase mRNAs are
upregulated in the mouse tumors (Fig. 4f). Together with the
identiﬁcation of DOT1L mutations in human melanomas, these
data suggest a UVR protective role for DOT1L in melanocytes.
Our data suggest that DOT1L deletion alone is insufﬁcient to
induce melanoma. To identify any potential cooperation between
the common oncogenic alterations with DOT1L mutation in
melanoma development, we ﬁrst analyzed the relationship
between BRaf/NRas status and DOT1L status in the TCGA
melanoma cohort. By using CBioPortal37,38 analysis (Supple-
mentary Fig. 5b), DOT1L mutations were found to partially co-
exist with BRaf and/or NRas mutation(s). Then we examined
BRaf and NRas status in DOT1L-null mouse melanomas and
found that BRaf (V637, homolog to human BRaf V600)
mutations are frequently observed in melanomas from Dot1l-
null transgenic mice (n = 4/7) (Supplementary Fig. 5c). Mutations
of NRas (Q61, G12, and G13) were not detected in Dot1l-null
mouse melanomas (Supplementary Fig. 5c).
Our data indicate that DOT1L loss of function alone is
insufﬁcient to induce melanoma development. Speciﬁcally,
melanoma was observed in UVB-irradiated Dot1l-null mice,
but not in unirradiated Dot1l-null mice. These data are consistent
with previous reports that dysfunction of a single signaling
pathway is not sufﬁcient to induce melanoma development
in vivo. For example, it is reported that 82% of benign nevi carry
the same mutation in BRAF as observed in melanoma39.
However, if another pathway is disrupted, e.g., through depletion
of the tumor-suppressor gene PTEN, mice develop melanoma at
age 2 months40. In the current study, nevi were not observed in
Dot1l-null mice. Furthermore, gene expression proﬁling of
human melanomas also indicates that, unlike BRAF mutations,
DOT1L loss-of-function mutations have no correlation with the
expression of MITF and PAX3, key regulators of melanoma
biology.
DOT1L is involved in NER through interacting with XPC.
Next, we focused on the role of DOT1L in the UVR response in
melanocytes, as almost all DOT1L mutations are UV signature
mutations (Fig. 1c and Supplementary Data 3), and UV irradia-
tion is required in Dot1l-null-driven melanoma development
(Fig. 4b). To identify how DOT1L protects against UVR in
melanocytes, we examined UV response of melanoma cells with
WT or different DOT1L mutants and found that melanoma cells
with mutant DOT1L are more sensitive to UV irradiation than
cells with WT DOT1L (Fig. 5a). Next, HPMs with DOT1L
silencing were irradiated with different doses of UVB and cell
viability was determined using the MTT assay 12 h after UVR.
Similarly, HPMs silenced for DOT1L were also more sensitive to
UVB irradiation (Fig. 5b). Moreover, re-expression of WT but
not mutant DOT1L in DOT1L-silenced HPMs increased viability
following UVR compared to re-expression of DOT1L mutants
(Fig. 5c). Consistent with the protective role of DOT1L in UVR
response, treatment of melanoma cells with the DOT1L inhibitor
EPZ-5676 decreased cell viability following UVR (Supplementary
Fig. 6a). Collectively these data suggest that DOT1L is a protective
factor for UVR in melanocytes.
The increased sensitivity of DOT1L mutant cell lines to UVR
suggested that DOT1L-mediated H3K79 methylation may have a
role in DNA repair following UVR-induced damage. UVB
irradiation mainly induces two types of DNA lesions (damage),
6–4 PPs and CPDs41. Using enzyme-linked immunosorbent
assays, we found that CPDs and 6–4 PPs photoproducts were
signiﬁcantly less efﬁciently repaired in melanoma cells with
DOT1L mutations than that in those with WT DOT1L (Fig. 5d
and Supplementary Fig. 6b). To determine whether there is a
direct involvement of DOT1L/methylated-H3K79 in DNA repair
after UVR exposure, we also assessed whether DOT1L silencing
or inhibition inﬂuences DNA repair after UVB irradiation in
HPMs. CPDs and 6–4 PPs were measured after UVB irradiation
(100 J m−2) in isolated HPMs stably expressing shDOT1L. Stable
expression of two different shRNAs directed against DOT1L in
HPMs led to a signiﬁcantly reduced capacity to repair UV-
induced DNA damage (Fig. 5e) compared to cells expressing a
control shRNA. To eliminate the possibility of off-target effects
associated with shRNA treatment, we reintroduced WT-DOT1L
or mutant DOT1L (M55L, P271L, or P505L) into DOT1L-
depleted cells and found that WT but not mutant DOT1L
restored efﬁcient DNA repair (Fig. 5f). Similar results were
obtained using the DOT1L inhibitor EPZ-5676 (Supplementary
Fig. 6c). CRISPR/Cas9 engineered DOT1L knockdown in HPMs
and mouse B16 melanoma cells, which were pooled as
heterogeneous transfected cells after drug selection, also failed
to affect cell viability (Supplementary Fig. 7a, b) unless cells were
UVB irradiated (Supplementary Fig. 7c). Sensitivity of the
CRISPRR/Cas9-mediated DOT1L knockdown cells correlated
with decreased capacity to repair CPDs and 6–4 PPs (Supple-
mentary Fig. 7d, e). Together, these results indicate that DOT1L
facilitates DNA repair after UVB irradiation in vitro.
Studies show that Dot1 and H3K79 methylation are required
for NER with yeast, in which methylated H3K79 seems to serve as
a docking site for the repair machinery on the chromatin42. In
addition, NER Dot1l-dependent H3k79me has been indicated to
potentially function in yeast to coordinate various repair
processes, such as heterochromatin-mediated silencing, post-
replication43. However, in mouse embryonic ﬁbroblasts Dot1l is
required at the transcription recovery stage following the removal
of damaged DNA, but not during the repair process44. The
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02687-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:259 |DOI: 10.1038/s41467-017-02687-7 |www.nature.com/naturecommunications 7
00.2
0.4
0.6
0.8
1
0 60 120
0
0.2
0.4
0.6
0.8
1
0 60 120
0
0.2
0.4
0.6
0.8
1
0 60 120
b c
CPD
a
CPD
6-4PP
e fd HPMs HPM DOT1L shRNA#1 cells
R
el
at
iv
e 
ph
ot
op
ro
du
ct
s
R
el
at
iv
e 
ph
ot
op
ro
du
ct
s
R
el
at
iv
e 
ph
ot
op
ro
du
ct
s
R
el
at
iv
e 
ph
ot
op
ro
du
ct
s
HPMs
1
0.1
0.01
HPM DOT1L shRNA#1
1
0.1
0.01
0 50
UVB (J m–2)
100 250 0 50
UVB (J m–2)
100 250 0 50
UVB (J m–2)
100 250
0.01
0.1
1
R
el
at
iv
e 
ce
ll 
vi
ab
ilit
y
R
el
at
iv
e 
ce
ll 
vi
ab
ilit
y
R
el
at
iv
e 
ce
ll 
vi
ab
ilit
y
Melanoma cell lines
***
*
**
** *
0
0.2
0.4
0.6
0.8
1
0 60 120
Time (min) after UVB
CPD
Melanoma cell lines
R
el
at
iv
e 
ph
ot
op
ro
du
ct
s
**
Time (min) after UVB
R
el
at
iv
e 
ph
ot
op
ro
du
ct
s
Time (min) after UVB
Time (min) after UVB
Time (min) after UVB
Time (min) after UVB
CPD DAPIMerge XPC
Control
EPZ-5676
CPD DAPIMerge XPC
shControl
shDOT1L
g
h
i
j
170 kDa -
130 kDa -
IP: IgG    IP: XPC
– + – +UVB
WCLDOT1L
DOT1L
XPC
XPC
DOT1L
XPC
IP: IgG    IP: DOT1L
– + – +UVB
– +UVB
β-Actin41 kDa -
170 kDa -
170 kDa -
130 kDa -
130 kDa -
XPC
DOT1L
H3K79me2
H3
shControl shDOT1L
UVB    – + – +  
130 kDa -
170 kDa -
18 kDa -
18 kDa -
*
**
*
0
0.2
0.4
0.6
0.8
1
1.2
R
el
at
iv
e 
XP
C/
CP
D 
(%
) 
***
0
shC
ont
rol
shD
OT
1L
Con
trol
EP
Z-5
676
0.2
0.4
0.6
0.8
1
1.2
R
el
at
iv
e 
XP
C/
CP
D 
(%
) 
***
H3K79me2
XPC
IP: IgG    IP: XPC
– + – +UVB
130 kDa -
18 kDa -
WCL
XPC
H3K79me2
– +UVB
β-Actin41 kDa -
130 kDa -
18 kDa -
k
0
0.2
0.4
0.6
0.8
1
0 60 120
0
0.2
0.4
0.6
0.8
1
0 60
6-4PP6-4PP
120
Control shRNA
DOT1L shRNA#1
DOT1L shRNA#2
Control EV
DOT1L WT
DOT1L M55L
DOT1L P271L
DOT1L P505L
C021 WT
D11
D28
D22 M
ut
an
t
C025
C021 WT
D11
D28
D22 M
ut
an
t
C025
C021 WT
D11
D28
D22 M
ut
an
t
C025
Control shRNA
DOT1L shRNA#1
DOT1L shRNA#2
Control shRNA
DOT1L shRNA#1
DOT1L shRNA#2
Control EV
DOT1L WT
DOT1L M55L
DOT1L P271L
DOT1L P505L
Control EV
DOT1L WT
DOT1L M55L
DOT1L P271L
DOT1L P505L
Chromatin Fractionation
Fig. 5 DOT1L/methylated H3K79 is involved in NER on UVB-induced DNA damage through interacting with XPC. a Melanomas from Queensland,
Australia were irradiated with different doses of UVB. Cell viability was measured by MTT assay 24 h after UVB irradiation. b HPMs with stable shDOT1L
or shControl were irradiated with different doses of UVB as indicated. Cell viability was measured by MTT assay 24 h after UVB irradiation. c WT or
different DOT1L mutants as indicated was introduced into HPMs with stable shDOT1L expression. The resulting cells were irradiated with different doses of
UVB as indicated. Cell viability was measured by MTT assay 24 h after UVB irradiation. d–fMelanomas from Queensland, Australia (d), HPMs with stable
shDOT1L expression (e), or HPMs with stable shDOT1L expression and WT or different mutant DOT1L reintroduction (f) were irradiated with 100 J m−2
UVB and then collected at different time points as indicated after UVB irradiation. Genomic DNA was extracted and photoproducts were detected. g, h
HPM cells treated with EPZ-5676 or vehicle control (g) or DOT1L depletion or shControl (h) were subjected to 100 J m−2 UVB under 5 µm micropore ﬁlter
and were co-stained for CPD and XPC after 0.5 h. Scale bar, 20 μm. i The whole-cell extracts from HPM subjected to 100 J m−2 UVB were prepared for Co-
IP assay to test the interaction of DOT1L with XPC. j The whole-cell extracts from HPM subjected to 100 J m−2 UVB were prepared for Co-IP assay to test
the interaction of XPC with H3K79me2. k HPMs with DOT1L depletion or shControl were exposed to 100 J m−2 UVB. After 0.5 h, the chromatin fraction
was prepared for western blot. *p< 0.05, **p< 0.01, ***p< 0.001, unpaired Student’s t-test. Error bars represent ± s.d.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02687-7
8 NATURE COMMUNICATIONS |  (2018) 9:259 |DOI: 10.1038/s41467-017-02687-7 |www.nature.com/naturecommunications
speciﬁc function of DOT1L and methylated H3K79 in NER in
mammalian cells such as melanocytes therefore remains unclear.
To decipher the role of DOT1L in melanocyte DNA repair, we
ﬁrst asked whether its expression was induced by UVB
irradiation. Speciﬁcally, HPMs were irradiated with 100 J m−2
UVB and the expression of DOT1L and methylated H3K79 were
detected. UVR-induced p53 upregulation served as a positive
control. Interestingly, the expression of DOT1L protein and
methylated H3K79 were stable at different time points after UVR
while p53 expression was robustly upregulated (Supplementary
Fig. 8a). These results indicate that DOT1L/methylated H3K79-
regulated DNA repair is not mediated through the upregulation
of DOT1L expression.
NER is an important DNA repair mechanism that removes
UVR-induced DNA damage45. Next, we measured the levels of
some NER factors (including XPA, XPC, DDB1, DDB2, ERCC1,
and p62) after UVB irradiation in melanocytes with stable
DOT1L silencing to determine whether DOT1L/methylated
H3K79 regulates the expression of co-factors in DNA repair
(Supplementary Fig. 8b). We found that UVB irradiation did not
alter the expression of NER factors. We also found that the
protein expression of XPA, XPC, DDB1, DDB2, ERCC1, and p62
were DOT1L and methylated H3K79 independent (Supplemen-
tary Fig. 8b). These results suggest that DOT1L-regulated DNA
repair is not mediated through the transcription regulation of
these genes implicated in NER9, a conclusion substantiated using
gene array analysis (see below).
As DOT1L does not appear to regulate the expression of DNA
repair factors, we therefore assessed whether DOT1L is required
for the recruitment of NER proteins to sites of damage. We stably
knocked down DOT1L or used a DOT1L inhibitor EPZ-5676 in
HPMs, and then irradiated those cells with 100 J m−2 UVB under
a 5 µm micropore ﬁlter46,47. Then we co-stained the cells with
antibodies against CPD and NER proteins including DDB1,
DDB2, XPC, XPA, ERCC1, and p62. Our results showed that the
co-localization of DDB1/DDB2 with CPD was not affected by
DOT1L knockdown, while the recruitment of XPC, XPA, ERCC1,
and p62 to CPD were strongly suppressed (Fig. 5g, h and
Supplementary Fig. 8c). These data suggested that DOT1L/
H3K79 methylation is required for recruitment of XPC and its
downstream factors XPA and p62 in NER in response to UV
irradiation. In addition, to conﬁrm the role of DOT1L on
recruiting XPC, we immunoprecipitated DOT1L in HPMs treated
with100 J m−2 UVB exposure, and the interaction between
DOT1L and XPC was detected (Fig. 5i). To identify whether
DOT1L-depdendent H3K79me2 also forms complex with XPC,
we also performed co-immunoprecipitation in UV-radiated
HPMs. We found that XPC interaction with H3K79me2 is in a
UVB-dependent manner (Fig. 5j). We also performed the
chromatin fractionation assays to determine whether the binding
of XPC to damaged DNA chromatin is dependent on DOT1L.
The results showed that DOT1L was required for efﬁcient XPC
recruitment to chromatin in response to UVB-induced DNA
damage (Fig. 5k). Taken together, these results showed that UVB
exposure led to the formation of the complex that consisted of
DOT1L/methylated H3K79 and XPC. In addition, we found that
DOT1L recruitment on chromatin was not changed in response
to UVB-induced DNA damage (Fig. 5k). This result is consistent
with the data that methylation of H3K79 was not changed in
response to DNA damage (Supplementary Fig. 8a–b). We further
showed that the interaction with XPC was mediated by DOT1L
amino acids 580–1138 (Supplementary Fig. 8d). These data
suggest that DOT1L interacts with XPC and is required for DNA
damage repair. Taken together, these results suggest that DOT1L
and H3K79 methylation provided a template for XPC to perform
NER in melanocytes.
A recent report demonstrated a direct interaction between
histone and XPC, through which histone deacetylation modulates
the localization and functions of XPC in the process of DNA
damage recognition for NER48. Here we show that DOT1L/
H3K79 methylation also plays the crucial role on the regulation of
XPC recognition of DNA lesion and modulates the interaction
between XPC and histones. Previous work indicates that
methylation of H3K79 potentially modulates the nucleosome
surface, leading to changing interactions of macromolecules with
the nucleosome49, which is consistent with our discovery that
DOT1L-dependent H3K79 methylation modulates XPC interac-
tion with histones and recognition of UVR-induced DNA damage
site for NER. Together these data indicate that histone
modiﬁcation-related chromatin structure is essential for XPC
function, and the histone modiﬁcation is crucial in the process of
DNA damage recognition for NER. However, the speciﬁc
underlying molecular mechanisms still require further
investigation.
To further clarify the connection between DOT1L/methylated
H3K79 and DNA repair, we analyzed our ChIP-seq data to
identify the DNA regions that show different levels of H3K79me2
between C021-shControl and C021-shDOT1L as well as between
C021-shControl and C025-shControl. Speciﬁcally, enrichment
analysis for the H3K79me2 signal was performed by MACS2 and
signiﬁcant difference was determined by log-transformed like-
lihood ratio (logLR) (logLR cutoff is 3, i.e. likelihood ratio = 1000)
50. This yielded 4425 regions with signiﬁcantly reduced
H3K79me2 levels in C021-shDOT1L and 1947 regions with
signiﬁcantly reduced H3K79me2 levels in C025-shControl, of
which 1647 regions have reduced H3K79me2 level in both
conditions. Thus the majority of downregulated H3K27me2 sites
found in C025-shControl (DOT1L mutant) are also observed
with decreased H3K79me2 levels in C021 cells treated with
shDOT1L. Next, we identiﬁed 1518 genes whose gene body
regions contain any of the 1647 regions with reduced H3K79me2
levels in both DOT1L-mutant C025 and shDOT1L-treated
C021 cells (some of the genes are associated with multiple
enriched regions). Gene Set Enrichment Analysis51 that extracted
the gene sets from the KEGG database52 revealed that genes were
signiﬁcantly enriched in multiple pathways (Supplementary
Fig. 9), and the number of genes observed in each gene set and
the associated p value is listed (Supplementary Data 5). As DNA
repair must take place in the context of chromatin, these
H3K79me2 enriched genes may suffer from DNA damage if
DOT1L is inhibited or mutated. DNA damage in these important
pathways may contribute to oncogenesis. Examples of enrich-
ment of H3K79me2 at a selection of individual genes such as
DDB1 and RAD23A are presented in Supplementary Fig. 10.
In addition, we proﬁled gene expression by microarray for
C021 with DOT1L knockdown, C025 with shControl, and EPZ-
5676-treated C021 with shControl. The results showed that C021
had a different transcriptional proﬁle of NER genes in
comparison to that of C025, which might be caused by cell line
speciﬁcity as they are derived from different melanoma patients.
However, in the same cell line background, the DOT1L knock-
down had only a very modest impact on NER gene expression
(fold change from −1.3 to 1.2), a result supported by the gene
expression proﬁle from C021 cells treated with the DOT1L
inhibitor EPZ-5676 (Supplementary Data 6). Speciﬁcally, we
obtained log2-transformed expression values for 23786 Entrez
Genes using Human Gene 2.0 ST arrays as described in the
Methods. We found that 10,117 genes (42.5%) were signiﬁcantly
differentially expressed (false discovery rate (FDR) q< 0.05)
between the C025 and C021 cells, which were derived from
different melanoma patients. We also performed another
microarray assay with C021-shDOT1L and C021-shControl and
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found 1656 genes (6.96%) with signiﬁcantly differential expres-
sion (FDR q< 0.05). Among those, 1010 genes (4.25%) were
downregulated more than two folds by DOT1L knockdown,
which include CYP21A2, BANCR, CST1, MPZ, and OAS1 with
genes implicated in metabolic pathways representing the largest
set of DOT1L-targeted genes. Using KEGG Pathway(s) analysis,
we found that 129 genes in metabolic pathways were repressed for
more than two fold, including CYP21A2 (−2.4 fold), QPRT (−2.3
fold), ALDH1A1 (−2.2 fold), and TM7SF2 (−2.0 folds). Our
microarray also found that 19 genes associated with cell adhesion
molecules are potentially controlled by DOT1L at the transcrip-
tional level and 6 genes in cell cycle (Supplementary Data 7).
However, no critical genes implicated in NER were found to be
regulated by DOT1L. The microarray data can be accessed in the
Gene Expression Omnibus (GEO) in Series GSE103079 and
GSE103080. These data support our conclusion that DOT1L is
involved in DNA repair through recruiting the NER factors onto
DNA damage sites but is unlikely to affect repair through
regulation of NER genes at the transcriptional level.
Discussion
Dot1l and H3K79 methylation may serve as a docking site for the
repair machinery on chromatin and thus is required for yeast
NER42. Further research has conﬁrmed this function in NER and
also found that Dot1l and H3K79 methylation potentially play
multiple roles in the response to UV damage in yeast, including
post-replication and checkpoint function43. On the other hand, in
mouse embryonic ﬁbroblasts Dot1l is required at the transcrip-
tion recovery stage following the removal of damaged DNA but
not the repair process44. Here our data indicate that, in mela-
nocytes and melanoma, DOT1L and H3K79 methylation is
required for XPC recruitment and efﬁcient NER, and loss of
DOT1L leads to UV sensitivity and inefﬁcient removal of UV
photoproducts. DOT1L therefore plays an essential role in UVR-
stressed melanocytes to protect against the transition to mela-
noma. In addition, our work on melanocytes with conditional
knockout of Dot1l provides an UVR-dependent mouse model of
melanoma.
Our results suggest that DOT1L is similar to another histone
methyltransferase, Enhancer of Zeste Homolog (EZH2), in can-
cer53. As a polycomb protein, the role of EZH2 depends on
cofactors that differ by cell context and dosage53. In addition, the
oncogenic activity of EZH2 in castration-resistant prostate cancer
cells is polycomb independent but dependent on EZH2 phos-
phorylation at Ser54. Although DOT1L is not a typical polycomb
protein, its role is dependent on its binding partners and cellular
context. While inhibition of EZH2 reduced reprogramming efﬁ-
ciency and repressed the yield of induced pluripotent stem cell
(iPSC) colonies, inhibition of DOT1L by shRNA or a small-
molecule-accelerated reprogramming signiﬁcantly increased the
yield of iPSC colonies55. Whereas DOT1L interacts with MLL
oncogenic fusion proteins, such as AF4, ENL, ELL, and AF1012,13
to activate a proliferative transcriptional program in leukemia
cells, in melanocytes, DOT1L interacts with XPC to facilitate
DNA repair and prevent melanoma development.
To study melanoma biology, a number of suspected genetic
abnormalities involved in human melanoma susceptibility and
tumor progression have been exploited in mice. In comparison to
the Tyr-SV40E56 and Hgf/Sf mouse models57, the Dot1l
conditional-null mouse model is much more efﬁcient for the
development of melanoma, with melanoma being diagnosed in
nearly 50% of mice by 10 weeks after UVB irradiation. Further-
more, melanomas in UVB-irradiated Dot1l-null mice closely
mimic the vertical phase of human melanoma histologically. The
Dot1l-null mouse strain is therefore complementary to the
BRafV600E knock-in mouse melanoma model58 for melanoma
studies and will allow a better understanding of melanoma
etiology, especially sun-related melanoma studies (both patholo-
gic and physiologic) in ways that cannot be readily addressed with
cell culture-based studies alone.
Methods
Cell lines, animals, and UV exposure. All cell lines were from ATCC, authen-
ticated by ATCC, and mycoplasma negative. Cell lines and UV exposure were as
described59. Brieﬂy, Cells were washed by phosphate-buffered saline (PBS) twice
before UVB irradiation. For the in vitro UV experiments, cells were exposed to
UVR in the Stratalinker UV chamber (Stratagene, Cedar Creek, TX, USA) with
UVB bulbs (UVP LLC, Upland, CA, USA). UV emittance was measured with the
use of a UV photometer (UVP LLC, Upland, CA, USA)59. Adherent cells were
irradiated through a small volume of PBS at a dose of 100 J m−2. An UVB dose of
100 J m−2 is equivalent to one standard erythema dose of UVB (SED), commonly
used as a measurement of sunlight. As a reference, the ambient exposure over an
entire sunny summer day in Europe (Switzerland) is approximately 30–40 SED60.
Human primary melanocytes were isolated from normal discarded foreskins as
described61 and were cultured in Medium 254 (Thermo Fisher Scientiﬁc Inc.,
Waltham, MA, USA). DOT1Lﬂox/ﬂox mice were provided by Dr. Jay Hess35. Brieﬂy,
the DOT1Lﬂox/ﬂox construct was designed such that three loxP sites were intro-
duced into DOT1L exons containing DOT1L catalytic domain8,62. Transgenic mice
expressing Cre-ERT2 protein under the control of the tyrosinase (Tyr) promoter
were purchased from Jackson Laboratory36. Mice underwent tamoxifen treatment
to silence DOT1L expression in melanocytes. Brieﬂy, mice at 3 weeks of age were
administered with tamoxifen in corn oil daily by intraperitoneal injection (Sigma,
CAT#T5648) at 0.12 mg g−1 body weight for 5 consecutive days. The control mice
will get plain corn oil (vehicle of tamoxifen) injection. Mouse UV exposure pro-
cedure were performed as described33. Brieﬂy, a UVB dose of 500 J m−2 was used.
This does is equivalent to one minimum erythema dose of UVB and 5 SED,
commonly used as a measurement of sunlight in vivo.
None of the experiments exceeded the limit, of which maximal tumor size is 20
mm at the largest diameter permitted by IACUC of Boston University Medical
Campus. Mice were maintained in a speciﬁc pathogen-free facility of the Animal
Science Center of Boston University Medical Campus, and the experiments were
performed according to the Institutional Animal Care and Use Committee of
Boston University Medical Campus. Mice were housed on a time cycle of 12 h of
light (beginning at 0600 hours) and 12 h of dark (beginning at 1800 hours). Mice
were allowed free access to an irradiated diet and sterilized water. The mice were
monitored daily for signs of health status and distress. Mice aged from 8 weeks to
6 months were used for breeding and pregnant females were placed in a new cage.
Mice were weaned at 20–21 days of age. DNA was extracted from the mouse tail
biopsy for genotyping. NCr nude mice (female, 8–10 weeks) were purchased from
Taconic Biosciences.
Real-time qPCR. The cDNA (40 ng) was used for qPCR ampliﬁcation with SYBR
green PCR master mix (Applied Biosystems, Invitrogen, Thermo Fisher Scientiﬁc
Inc.). Samples in which no reverse transcriptase was added were included for each
RNA sample. The relative levels of expression of genes were normalized according
to those of GAPDH. Real-time qRT-PCR data were calculated using the com-
parative Ct method as previously described63. All qPCR was performed in tripli-
cate, and three independent RNA samples were assayed for each time point. The
primers for determining relative Pax3, Tyrosinase, hDOT1L, and mDot1l transcript
levels were: mPax3 forward: 5′-TTTCACCTCAGGTAATGGGACT-3′, reverse: 5′-
GAACGTCCAAGGCTTACTTTGT-3′; mTyrosinase forward: 5′-CGATGGAA-
CACCTGAGGGAC-3′, reverse: 5′-TGTTCAAAAATACTTCCAGTGTGT-3′;
hDOT1L forward: 5′-GAGACCTCCTTCGACCTGGT-3′, reverse: 5′-CGACGC-
CATAGTGATGTTTGC-3′; and mDot1l forward: 5′-CAACTGCAAA-
CATCACTACGGA-3′, reverse: 5′-TCACCTCGTTCCAGTGTGTAT-3′.
Bioinformatics analysis. SNP6 data were analyzed by GISTIC2.0. DOT1L
mutations from TCGA were annotated by ANNOVAR, GATK, and MuTect/
VarScan. Mutation damage effects were predicted using SIFT 4.0.5 or PolyPhen
2.2.2. DOT1L mutations from Queensland, Australia were analyzed using two NGS
platforms (Illumina Genome Analyzer II and Life Technologies SOLiD) and
mapped reads with platform-appropriate alignment programs64.
Microarray. All arrays were performed by BU Microarray Sequencing Resource.
Speciﬁcally, C025 cells (DOT1L mutation) and C021 cells (DOT1L WT) treated
with DOT1L inhibitor, EPZ-5676, or vehicle control were exposed to 100 J m−2
UVB, and 3 h later the RNA was prepared with the RNeasy Mini Kit (74104)
(Qiagen, Hilden, Germany) for microarray assay. C021 cells with DOT1L knock-
down and Scramble control were used for RNA extraction with the RNeasy Mini
Kit (Qiagen, Hilden, Germany) for microarray assay. The arrays were normalized
together using the Robust Multiarray Average algorithm and a CDF (Chip Deﬁ-
nition File) that maps the probes on the array to unique Entrez Gene identiﬁers.
The expression values are log2-transformed by default. The technical quality of the
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arrays was assessed by two quality metrics: Relative Log Expression (RLE) and
Normalized Unscaled Standard Error (NUSE). For each sample, median RLE
values >0.1 or NUSE values >1.05 are considered out of the usual limits, although
RLE is the quality metric most strongly associated with technical quality. All arrays
had median RLE and NUSE values well within these limits. Principal Component
Analysis was then performed. Benjamini–Hochberg FDR correction was applied to
obtain FDR-corrected p values (q values), which represent the probability that a
given result is a false positive based on the distribution of all p values on the array.
In addition, the FDR q value was also recomputed after removing genes that were
not expressed above the array-wise median value of at least one array.
ChIP-seq analysis. ChIP-seq was performed as previously described65. Brieﬂy,
cells were ﬁrst cross-linked by 1% formaldehyde and then lysed. The chromatin
extract was sonicated for 15 min using a Diagenode bioruptor and then pulled
down by an antibody recognizing H3K79me2 (Abcam ab3594) with 2 µg for each
IP. Enriched DNA was released by de-crosslinking at 65 degree for 6 h and
extracted by the Qiagen MinElute PCR Puriﬁcation Kit (Qiagen 28006). DNA
sequencing libraries were generated using the NEB ChIP-seq Library Preparation
Kit (E6200S) and sequenced on an Illumina MiSeq (50-bp single-end reads).
Sequencing reads were aligned to the hg19 reference genome by the
Burrows–Wheeler Aligner66, and H3K79me2-binding sites were called by
MACS250. Differential binding peaks were called by MACS2 “bdgdiff” function and
their closest genes were called by the GREAT pipeline67. Two biological replicates
were included for each condition. The ChIP-seq data have been deposited at GEO
(GSE89029).
Plasmids and RNA interference. HA-DOT1L were generously provide by Dr. Yi
Zhang, HHMI and Harvard12. The mutant DOT1L constructs were generated
using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies,
Santa Clara, CA). LentiCRISPR v2 constructs for human DOT1L or mouse Dot1l
were generated following the online guide provided by Dr. Feng Zhang, Broad
Institute and MIT (http://crispr.genome-engineering.org/)68. LentiCRISPR v2
constructs speciﬁc for human DOT1L or mouse Dot1l were transfected into HPM
or B16 cells by lentivirus infection. The cells were selected with puromycin and
then pooled as heterogeneous transfected cells. Ambion Silencer Select DOT1L
(4392420) siRNA were purchased form Thermo Fisher Scientiﬁc Inc. (Waltham,
MA, USA). The HA-DOT1L truncations were generated with the following pri-
mers (5′ to 3′): (1–586) fraction, forward, ATAGTAGAATTCACATGGGGGA-
GAAGCTGGAGC, reverse, ATAGTACTCGAGCTACTAGTCCTGCT
CCAGCTGCTCCGACTGC; (580–1138) fraction, forward, ATAGTA-
GAATTCACCAGTCGGAGCAGCTGGAGCAGGAC, reverse, ATAGTACTC-
GAGCTACTACAGGGGCTGGTTGATGTTACTGACCATC; (1131–1537)
fraction, forward, ATAGTAGAATTCACGTCAGTAACATCAACCAGCCCCTG;
reverse, ATAGTACTCGAGCTACTAGTTACCTCCAACTGTGCCGCCTGC-
CAC; (1–1138) fraction, forward, ATAGTAGAATTCACATGGGGGA-
GAAGCTGGAGC, reverse, ATAGTACTCGAGCTACTACAGGGGCTGGTTGA
TGTTACTGACCATC; and (580–1537) fraction, forward, ATAGTA-
GAATTCACCAGTCGGAGCAGCTGGAGCAGGAC, reverse, ATAGTACTC-
GAGCTACTAGTTACCTCCAACTGTGCCGCCTGCCAC. shRNA constructs
targeting human DOT1L (RHS4533-EG84444) were purchased from Open-
Biosystems. The most efﬁcient knockdown cell lines with shDOT1L (target
sequence: 5′-ATAGCGAGCTTGAGATCCGGG-3′) were used in assays.
Transfection, lentiviral, and retroviral infections. To generate stable knockdown
of DOT1L in B16 and HPMs, mouse- or human-speciﬁc shRNAs in PLKO1 against
DOT1L were co-transfected with psPAX2 (Addgene #12260) and pMD2.G
(Addgene, #12259) in HEK293-FT (ATCC) using Lipofectamine 2000 (Invitrogen,
Thermo Fisher Scientiﬁc Inc). Lentiviruses were collected after 48 h and then
infected cells for 24 h in the presence of polybrene (8 μg mL−1) and selected with
puromycin (2 μg mL−1). To generate cells with stable expression of WT DOT1L
and mutant DOT1L, HEK293T cells were co-transfected with DOT1L constructs in
pQCXIP, VSV-G, and pUMVC (Addgene #8449) plasmids using Lipofectamine
2000. Retroviruses were harvested after 48 h and cells with shDOT1L were infected
with retroviruses in the presence of polybrene (8 μg mL−1). After 24 h, cells were
selected with puromycin (2 μg mL−1).
Clonogenic survival and soft agar assays. The clonogenic survival and soft agar
assays for hTERT/p53DD/CDK4(R24C) melanocytes were performed as descri-
bed32. Brieﬂy, hTERT/p53DD/CDK4(R24C) melanocytes with or without DOT1L
depletion were treated with 20 J m−2 UVB for 14 days before plating into six-well
plate at 1000 cells per well. For soft agar assays, cells (10,000 per well) were seeded
in 0.5% low-melting-point agarose in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) with 10% fetal bovine serum (FBS) and layered onto 0.8% agarose in
DMEM with 10% FBS. The plates were kept in the cell culture incubator for
30 days after which the colonies >50 μm were counted under a light microscope.
All results were calculated by three independent experiments.
Immunoblot analysis. The following antibodies used in Western blotting were
purchased from Cell Signaling Technology (Danvers, MA, USA): anti-HA-tag
(6E2) (1:1000, #2367, Cell Signaling Technology), anti-p53 (7F5) (1:1000, #2527,
Cell Signaling Technology), anti-DDB-1 (D4C8) (1:1000, #6998, Cell Signaling
Technology), anti-DDB-2 (D4C4) (1:1000, #5416, Cell Signaling Technology) anti-
ERCC1 (1:1000, #3885, Cell Signaling Technology), and anti-XPC (D1M5Y)
(1:1000, #14768, Cell Signaling Technology). The Polyclonal anti-KMT4/DOT1L
(1:2000, ab72454, Abcam) antibody, anti-XPA (1:2000, ab85914, Abcam), poly-
clonal di-methylated H3K79 antibody (1:1000, ab3594, Abcam), polyclonal to
mono-methylated H3K79 antibody (1:500, ab2886, Abcam), and polyclonal tri-
methylated H3K79 antibody (1:1000, ab2621, Abcam) were purchased from
Abcam. TFIIH p62 Antibody (1:500, Q-19) was purchased from Santa Cruz Bio-
technologies, Inc. Other antibodies include monoclonal Anti-β-Actin-Peroxidase
antibody (1:25000, AC-15, Sigma Aldrich), monoclonal ANTI-FLAG® M2 anti-
body (1:1000, Sigma Aldrich), and anti-H3 (1:500, 865R2, Thermo Fisher Scientiﬁc
Inc.). Most important uncropped blot images are shown in Supplementary Fig. 11.
Immunohistochemistry. Tissue samples for immunohistochemistry analysis were
sectioned at 4 µm thick and underwent antigen heat retrieval using EDTA 105 °C
for 10 min. Antibodies include: anti-S-100 (1:100, Dako North America, Inc.
Carpinteria, CA, USA), anti-Tyrosinase (1:100, T311, Dako North America), anti-
Pax3 (1:100, 38-1801, Thermo Fisher Scientiﬁc Inc.), and Melan-A/MART-1
antibody (1:500, M2-9E3, Novus Biologicals, USA). Negative controls were pro-
cessed in parallel using an identical protocol but with the omission of the primary
antibody. Dako EnVision+ System HRP Kit was used in immunohistochemistry.
Immunoﬂuorescence. Immunoﬂuorescence were performed according to stan-
dard protocols with the following antibodies: anti-XPC (1:200, D1M5Y, Cell Sig-
naling), anti-XPA (1:200, ab85914, Abcam), anti-CPD (1:50, KTM53, Kamiya
Biomedical Company), anti-TFIIH p62 (1:50, Q-19, Santa Cruz Biotech) anti-
DDB-1 (1:100, ab97522, Abcam), anti-DDB-2 (10 µg mL−1, ab51017, Abcam), and
anti-ERCC1 (1 µg mL-1, ab2356, Abcam). All slides were cover-slipped using
Vectashield-DAPI mounting media (Vector laboratories, Burlingame, CA, USA).
Images per sample were captured using the Leica SP5 Confocal Microscope at BU
Cellular Imaging Core. To determine the relative ﬂuorescence at local irradiated
sites, the CPD-positive area was gated by the Image J software and ﬂuorescence
intensity was quantiﬁed. Then the ﬂuorescence intensity of XPC at the same area
was quantiﬁed and divided by the CPD ﬂuorescence. Relative ﬂuorescence was
calculated as the experimental ﬂuorescence divided by the control ﬂuorescence69.
Co-immunoprecipitation and chromatin fractionation assay. Brieﬂy, cells were
washed twice with ice-cold PBS and lysed in lysis buffer containing 50 mM Tris pH
7.4; 1% Triton X-100; 0.5 mM EDTA; 0.5 mM EGTA; 150 mM NaCl; 10% Glycerol;
1 mM phenylmethylsulfonyl ﬂuoride, and complete protease inhibitor cocktail
(Roche) on ice for 30 min. The supernatant was collected after centrifugation at
15,000 × g for 15 min at 4 °C, and 500 µg of total cell lysate was treated by DNase
(15 UmL−1, Pierce), precleared by 20 µL Protein G Agarose Beads (Thermo Fisher
Scientiﬁc Inc.), and then incubated with primary antibody, including anti-DOT1L
(ab72454, Abcam) and anti-XPC (#14768, Cell signaling) overnight at 4 °C. In all,
20 µl of Protein A/G Agarose Beads was added into the samples with rotation at 4 °
C for 1 h. After three washes with 1 mL of lysis buffer, the bound proteins were
released by boiling in 30 μL of sodium dodecyl sulfate loading buffer and detected
as described above. The chromatin fractionation was extracted with the Chromatin
Extraction Kit (ab117152, Abcam) from the cells and assayed with western blot.
In vivo tumorigenesis assay. In vivo tumorigenesis assay of hTERT/p53DD/
CDK4(R24C)/BRAFV600E melanocytes was performed as described previously32,
Brieﬂy, 3 × 106 control or DOT1L-depleted hTERT/p53DD/CDK4(R24C)/
BRAFV600E melanocytes were mixed with matrigel (1:1) and injected sub-
cutaneously into the ﬂanks of female nude mice. Tumor size was measured every
3 days with a caliper, and the tumor volume was determined as mentioned above.
The tumors were dissected to measure their weights 24 days after cell inoculation.
Enzyme immunoassay. Enzyme immunoassay was performed using the anti-CPD
(MC-062) and anti-6–4 PP (KTM-50) antibodies. Brieﬂy, the heat-denatured
genomic DNA was coated onto the microplate wells with Pierce DNA Coating
Solution (17250, Thermo Fisher Scientiﬁc Inc.). After washing and blocking by PBS
with the puriﬁed anti-mouse IgG mAb of 2 µg mL−1, the speciﬁc antibodies of anti-
CPD (MC-062) and anti-6–4 PPs (KTM-50) were diluted 1:1000 in blocking buffer
and added to each well. Optical density at 405 nm was determined.
Histone extraction and in vitro H3K79me2 assay. Cells (1 × 107) were used for
the total histone extracts. EpiQuik Total Histone Extraction Kit (OP-0006) and
EpiQuik Global Di-Methyl Histone H3K79 Quantiﬁcation Kit (P-3056) were
purchased from Epigentek Group Inc. (Farmingdale, NY, USA). Experiments were
carried out following the protocols provided by the company.
Statistical analysis. All quantitative data were presented as the mean ± SEM or
the mean± SD as indicated of at least three independent experiments by Student’s
t-test for between-group differences.
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Data availability. All data that support the ﬁndings of this study are available on
reasonable request from the corresponding author. The contributing authors
declare that all relevant data are included in the paper and its supplementary
information ﬁles. The microarray data can be accessed in the GEO in Series
GSE103079 and GSE103080. The ChIP-seq data have been deposited at GEO
(GSE89029).
Received: 23 December 2016 Accepted: 13 December 2017
References
1. Sinden, R. R. Molecular biology: DNA twists and ﬂips. Nature 437, 1097–1098
(2005).
2. Lian, C. G. et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of
melanoma. Cell 150, 1135–1146 (2012).
3. Zhang, Y. & Reinberg, D. Transcription regulation by histone methylation:
interplay between different covalent modiﬁcations of the core histone tails.
Genes Dev. 15, 2343–2360 (2001).
4. Ng, H. H., Ciccone, D. N., Morshead, K. B., Oettinger, M. A. & Struhl, K.
Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and
mammalian cells: a potential mechanism for position-effect variegation. Proc.
Natl. Acad. Sci. USA 100, 1820–1825 (2003).
5. Nguyen, A. T. & Zhang, Y. The diverse functions of Dot1 and H3K79
methylation. Genes Dev. 25, 1345–1358 (2011).
6. van Leeuwen, F., Gafken, P. R. & Gottschling, D. E. Dot1p modulates silencing
in yeast by methylation of the nucleosome core. Cell 109, 745–756 (2002).
7. Ng, H. H. et al. Lysine methylation within the globular domain of histone H3 by
Dot1 is important for telomeric silencing and Sir protein association. Genes
Dev. 16, 1518–1527 (2002).
8. Jones, B. et al. The histone H3K79 methyltransferase Dot1L is essential for
mammalian development and heterochromatin structure. PLoS Genet. 4,
e1000190 (2008).
9. Wood, R. D., Mitchell, M., Sgouros, J. & Lindahl, T. Human DNA repair genes.
Science 291, 1284–1289 (2001).
10. Tang, J. Y., Hwang, B. J., Ford, J. M., Hanawalt, P. C. & Chu, G. Xeroderma
pigmentosum p48 gene enhances global genomic repair and suppresses UV-
induced mutagenesis. Mol. Cell 5, 737–744 (2000).
11. Fuss, J. O. & Cooper, P. K. DNA repair: dynamic defenders against cancer and
aging. PLoS Biol. 4, e203 (2006).
12. Nguyen, A. T. et al. DOT1L regulates dystrophin expression and is critical for
cardiac function. Genes Dev. 25, 263–274 (2011).
13. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121,
167–178 (2005).
14. Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I. & Cleary, M. L. A higher-
order complex containing AF4 and ENL family proteins with P-TEFb facilitates
oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17,
198–212 (2010).
15. Krivtsov, A. V. et al. H3K79 methylation proﬁles deﬁne murine and human
MLL-AF4 leukemias. Cancer Cell 14, 355–368 (2008).
16. Daigle, S. R. et al. Potent inhibition of DOT1L as treatment of MLL-fusion
leukemia. Blood 122, 1017–1025 (2013).
17. Guan, J., Gupta, R. & Filipp, F. V. Cancer systems biology of TCGA SKCM:
efﬁcient detection of genomic drivers in melanoma. Sci. Rep. 5, 7857 (2015).
18. Ashburner, M. et al. Gene ontology: tool for the uniﬁcation of biology. The
Gene Ontology Consortium. Nat. Genet. 25, 25–29 (2000).
19. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of
genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38,
e164 (2010).
20. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat.
Protoc. 4, 1073–1081 (2009).
21. Li, B. & Leal, S. M. Methods for detecting associations with rare variants for
common diseases: application to analysis of sequence data. Am. J. Hum. Genet.
83, 311–321 (2008).
22. Wang, W. & Wei, Z. Collapsing singletons may boost signal for associating rare
variants in sequencing study. BMC Proc. 8, S50 (2014).
23. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251–263
(2012).
24. Shain, A. H. et al. Exome sequencing of desmoplastic melanoma identiﬁes
recurrent NFKBIE promoter mutations and diverse activating mutations in the
MAPK pathway. Nat. Genet. 47, 1194–1199 (2015).
25. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent
small-molecule DOT1L inhibitor. Cancer Cell. 20, 53–65 (2011).
26. Min, J., Feng, Q., Li, Z., Zhang, Y. & Xu, R. M. Structure of the catalytic domain
of human DOT1L, a non-SET domain nucleosomal histone methyltransferase.
Cell 112, 711–723 (2003).
27. Guenther, M. G. et al. Aberrant chromatin at genes encoding stem cell
regulators in human mixed-lineage leukemia. Genes Dev. 22, 3403–3408 (2008).
28. Gilan, O. et al. Functional interdependence of BRD4 and DOT1L in MLL
leukemia. Nat. Struct. Mol. Biol. 23, 673–681 (2016).
29. Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79
methylation by DOT1L. Cancer Cell. 20, 66–78 (2011).
30. Neff, T. & Armstrong, S. A. Chromatin maps, histone modiﬁcations and
leukemia. Leukemia 23, 1243–1251 (2009).
31. Wilkinson, A. C. et al. RUNX1 is a key target in t(4;11) leukemias that
contributes to gene activation through an AF4-MLL complex interaction. Cell
Rep. 3, 116–127 (2013).
32. Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage
survival oncogene ampliﬁed in malignant melanoma. Nature 436, 117–122 (2005).
33. Cao, J. et al. MC1R is a potent regulator of PTEN after UV exposure in
melanocytes. Mol. Cell 51, 409–422 (2013).
34. Chen, S. et al. Palmitoylation-dependent activation of MC1R prevents
melanomagenesis. Nature 549, 399–403 (2017).
35. Jo, S. Y., Granowicz, E. M., Maillard, I., Thomas, D. & Hess, J. L. Requirement
for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL
translocation. Blood 117, 4759–4768 (2011).
36. Bosenberg, M. et al. Characterization of melanocyte-speciﬁc inducible Cre
recombinase transgenic mice. Genesis 44, 262–267 (2006).
37. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical
proﬁles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
38. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
39. Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33,
19–20 (2003).
40. Dankort, D. et al. Braf(V600E) cooperates with Pten loss to induce metastatic
melanoma. Nat. Genet. 41, 544–552 (2009).
41. Wong, T. H. & Rees, J. L. The relation between melanocortin 1 receptor
(MC1R) variation and the generation of phenotypic diversity in the cutaneous
response to ultraviolet radiation. Peptides 26, 1965–1971 (2005).
42. Tatum, D. & Li, S. Evidence that the histone methyltransferase Dot1 mediates
global genomic repair by methylating histone H3 on lysine 79. J. Biol. Chem.
286, 17530–17535 (2011).
43. Bostelman, L. J., Keller, A. M., Albrecht, A. M., Arat, A. & Thompson, J. S.
Methylation of histone H3 lysine-79 by Dot1p plays multiple roles in the
response to UV damage in Saccharomyces cerevisiae. DNA Repair (Amst.) 6,
383–395 (2007).
44. Oksenych, V. et al. Histone methyltransferase DOT1L drives recovery of gene
expression after a genotoxic attack. PLoS Genet. 9, e1003611 (2013).
45. Cline, S. D. & Hanawalt, P. C. Who’s on ﬁrst in the cellular response to DNA
damage? Nat. Rev. Mol. Cell Biol. 4, 361–372 (2003).
46. Katsumi, S. et al. In situ visualization of ultraviolet-light-induced DNA damage
repair in locally irradiated human ﬁbroblasts. J. Invest. Dermatol. 117,
1156–1161 (2001).
47. Volker, M. et al. Sequential assembly of the nucleotide excision repair factors
in vivo. Mol. Cell 8, 213–224 (2001).
48. Kakumu, E. et al. Xeroderma pigmentosum group C protein interacts with
histones: regulation by acetylated states of histone H3. Genes Cells 22, 310–327
(2017).
49. Lu, X. et al. The effect of H3K79 dimethylation and H4K20 trimethylation on
nucleosome and chromatin structure. Nat. Struct. Mol. Biol. 15, 1122–1124
(2008).
50. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9,
R137 (2008).
51. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression proﬁles. Proc. Natl. Acad.
Sci. USA 102, 15545–15550 (2005).
52. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res. 28, 27–30 (2000).
53. Lund, K., Adams, P. D. & Copland, M. EZH2 in normal and malignant
hematopoiesis. Leukemia 28, 44–49 (2014).
54. Xu, K. et al. EZH2 oncogenic activity in castration-resistant prostate cancer
cells is Polycomb-independent. Science 338, 1465–1469 (2012).
55. Onder, T. T. et al. Chromatin-modifying enzymes as modulators of
reprogramming. Nature 483, 598–602 (2012).
56. Bradl, M., Klein-Szanto, A., Porter, S. & Mintz, B. Malignant melanoma in
transgenic mice. Proc. Natl. Acad. Sci. USA 88, 164–168 (1991).
57. Takayama, H. et al. Diverse tumorigenesis associated with aberrant
development in mice overexpressing hepatocyte growth factor/scatter factor.
Proc. Natl. Acad. Sci. USA 94, 701–706 (1997).
58. Dhomen, N. et al. Oncogenic Braf induces melanocyte senescence and
melanoma in mice. Cancer Cell 15, 294–303 (2009).
59. Cui, R. et al. Central role of p53 in the suntan response and pathologic
hyperpigmentation. Cell 128, 853–864 (2007).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02687-7
12 NATURE COMMUNICATIONS |  (2018) 9:259 |DOI: 10.1038/s41467-017-02687-7 |www.nature.com/naturecommunications
60. Diffey, B. L., Jansen, C. T., Urbach, F. & Wulf, H. C. The standard erythema
dose: a new photobiological concept. Photodermatol. Photoimmunol. Photomed.
13, 64–66 (1997).
61. Horikawa, T., Norris, D. A., Zekman, T. & Morelli, J. G. Effective elimination of
ﬁbroblasts in cultures of melanocytes by lowering calcium concentration in
TPA depleted medium following geneticin treatment. Pigment. Cell. Res. 9,
58–62 (1996).
62. Cheng, X., Collins, R. E. & Zhang, X. Structural and sequence motifs of protein
(histone) methylation enzymes. Annu. Rev. Biophys. Biomol. Struct. 34,
267–294 (2005).
63. Zhu, B. et al. TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle.
Oncogene 35, 4212–4224 (2015).
64. Stark, M. S. et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in
metastatic melanoma identiﬁed by exome sequencing. Nat. Genet. 44, 165–169
(2012).
65. Zhang, X. et al. Identiﬁcation of focally ampliﬁed lineage-speciﬁc super-
enhancers in human epithelial cancers. Nat. Genet. 48, 176–182 (2016).
66. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
67. McLean, C. Y. et al. GREAT improves functional interpretation of cis-
regulatory regions. Nat. Biotechnol. 28, 495–501 (2010).
68. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide
libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
69. Niida, H. et al. Phosphorylated HBO1 at UV irradiated sites is essential for
nucleotide excision repair. Nat. Commun. 8, 16102 (2017).
Acknowledgements
We thank Dr. Yi Zhang (Harvard and HHMI) and Dr. Guo Wei (The Broad Institute)
for reagents and helpful suggestion. This work was supported by the National Key R&D
Program of China (J.Z., 2017YFA0503502) and the National Natural Science Foundation
of China (J.Z., 31730050). This work was also supported by the Ofﬁce of the Assistant
Secretary of Defense for Health Affairs through the Peer Reviewed Cancer Research
Program under Award No. W81XWH-15-1-0109, Melanoma Research Foundation
Establish Investigator Award (R.C.), Hong Kong and Macao Young Scientists of the
National Natural Science Foundation of China (Grant No.81428025 for R.C.), Major
Projects of international Cooperation and Exchanges from National Natural Science
Foundation of China (X.C., 81620108024), and National Natural Science Foundation of
China (C.P.,81572679, X.G., 81630106). H.W. was supported by Innovative Research
Team in University of Ministry of Education of China (IRT1270). R.C. and W.W. are
American Cancer Society Research Scholars. N.H. is supported by a Senior Principal
Research Fellowship from the NHMRC, and C.R.G. is funded by the Ludwig Institute for
Cancer Research. Microarray was performed by the Boston University Microarray
Sequencing Resource (CTSA grant UL1-TR001430).
Author contributions
B.Z., S.C., H.W., C.Y., and C.H. performed most of the experiments. L.W. generated the
mutant DOT1L constructs. X.Z. performed and analyzed the CHIP-seq data. J.Z., Z.X.,
and Z.W. performed the bioinformatical analysis. C.L. reviewed all the histological
staining. D.L. performed the protein crystal analysis. C.P., Z.L., Z.X., P.M., S.P., T.W., X.
G., Y.S., M.L., W.W., J.P., Y.W., J.H., N.H., C.R.G., X.C., J.Z. and R.C. designed the
experiments. X.C., J.Z. and R.C. supervised the study. R.C. wrote the manuscript with
help from C.R.G., T.W., J.H., and N.H. All authors commented on the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
017-02687-7.
Competing interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02687-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:259 |DOI: 10.1038/s41467-017-02687-7 |www.nature.com/naturecommunications 13
